Bravura is “reconfiguring” its business … the stock crashes 55%!

Nick Sundich Nick Sundich, November 3, 2022

It is not often you hear company management admitting their firm needs to be reconfigured, but that’s just what Bravura Solutions’ (ASX:BVS) management did this morning. Shareholders have punished the stock sending it down by more than 50%. 

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

 

Bravura needs to be reconfigured

Bravura, a provider of software solutions for global financial institutions, had been undertaking a strategic review and provided shareholders with an interim update along with FY23 guidance. The company, using language you’d typically expect of external management consultants or short-seller firms, literally said,’ The business will be required to be reconfigured to scale our product across customers’.

While the review found that the company had solid foundations, the pace of change in the industry from a traditional services model to a technology solutions provider will require the company to realign itself to create “product discipline”. In other words, the company developed its products in every direction without much focus.

 

Bravura Solutions (ASX:BVS) share price chart

 

A soft FY23 expected

Adding insult to injury, Bravura announced a downgrade to analysts’ consensus forecasts. The company still expects modest revenue growth of $270-$275m (up from $266.7m in FY22), but expects EBITDA of $10-$15m and an NPAT between breakeven and a $5m loss. Considering it made $45.3m in EBITDA and a $25.7m NPAT last year, this would be an enormous drop. It also told shareholders it would suspend dividends until it had transitioned through the current reset. 

The company said that the repositioning would return it to a stronger footing, but investors are not hanging around for that, sending shares down more than 50%. Bravura’s market capitalisation is barely a tenth of what it was in January 2020, prior to the Corona Crash.

 

No time to do stock research, but you still want to invest?
 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

aml3d

AML3D Surges After Landing 9th US Order with A$1.7m ARCEMY X Deal

AML3D Extends US Momentum, Stock Rises on Major A$1.69m ARCEMY X Sale to FasTech AML3D (ASX: AL3) continues to build…

metallium

Metallium Signs Binding 10 Year Deal with New Frontier Minerals After Record Processing Results

Record FJH Results Drive Metallium’s Binding Ten-Year Deal with New Frontier Minerals Metallium (ASX: MTM) delivered a major step forward…

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): It has taken the plunge into a Phase 2 trial against T-Cell Lymphoma

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…